CY1108452T1 - IMIDAZOLI PRODUCTS AND USE THESE AS PERIODICALLY EXTRACTIVE INHIBITORS OF DOPOPAMIN-β-HYDROXYLUM - Google Patents

IMIDAZOLI PRODUCTS AND USE THESE AS PERIODICALLY EXTRACTIVE INHIBITORS OF DOPOPAMIN-β-HYDROXYLUM

Info

Publication number
CY1108452T1
CY1108452T1 CY20081101204T CY081101204T CY1108452T1 CY 1108452 T1 CY1108452 T1 CY 1108452T1 CY 20081101204 T CY20081101204 T CY 20081101204T CY 081101204 T CY081101204 T CY 081101204T CY 1108452 T1 CY1108452 T1 CY 1108452T1
Authority
CY
Cyprus
Prior art keywords
hydroxylum
dopopamin
imidazoli
extractive
inhibitors
Prior art date
Application number
CY20081101204T
Other languages
Greek (el)
Inventor
David Alexander Learmonth
Da Silva Patricio Manuel Viera Araujo Soares
Alexander Beliaev
Original Assignee
Bial - Portela & Ca., S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03256420A external-priority patent/EP1408038B1/en
Application filed by Bial - Portela & Ca., S.A. filed Critical Bial - Portela & Ca., S.A.
Publication of CY1108452T1 publication Critical patent/CY1108452T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Περιγράφονται ενώσεις του τύπου Ι και μέθοδος παρασκευής αυτών όπου Χ είναι CH2, Ο ή S, και n είναι 1, 2 ή 3, υπό την προϋπόθεση ότι, όταν το Χ είναι CH2, το n δεν είναι 1. Οι ενώσεις έχουν δυνάμει πολύτιμες φαρμακευτικές ιδιότητες για την θεραπεία καρδιοαγγειακών διαταραχών όπως είναι η υπέρταση και η χρόνια καρδιακή ανεπάρκεια.Compounds of formula I are described and a method of their preparation wherein X is CH 2, 0 or S, and n is 1, 2 or 3, provided that, when X is CH 2, n is not 1. The compounds have potentially valuable pharmaceuticals. properties for the treatment of cardiovascular disorders such as hypertension and chronic heart failure.

CY20081101204T 2002-10-11 2008-10-24 IMIDAZOLI PRODUCTS AND USE THESE AS PERIODICALLY EXTRACTIVE INHIBITORS OF DOPOPAMIN-β-HYDROXYLUM CY1108452T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0223719A GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0224306A GB2394223B (en) 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
EP03256420A EP1408038B1 (en) 2002-10-11 2003-10-10 Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase

Publications (1)

Publication Number Publication Date
CY1108452T1 true CY1108452T1 (en) 2014-04-09

Family

ID=9945777

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20081101204T CY1108452T1 (en) 2002-10-11 2008-10-24 IMIDAZOLI PRODUCTS AND USE THESE AS PERIODICALLY EXTRACTIVE INHIBITORS OF DOPOPAMIN-β-HYDROXYLUM
CY20111100639T CY1112457T1 (en) 2002-10-11 2011-07-01 CHROMO- AND THIROXROMANO-3-YlO-1,3-dihydro-imidazole as inhibitors of dopamine-B-hydroxylation, and their production methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100639T CY1112457T1 (en) 2002-10-11 2011-07-01 CHROMO- AND THIROXROMANO-3-YlO-1,3-dihydro-imidazole as inhibitors of dopamine-B-hydroxylation, and their production methods

Country Status (11)

Country Link
KR (1) KR101350741B1 (en)
CN (1) CN100393715C (en)
AR (2) AR041589A1 (en)
AT (5) ATE403652T1 (en)
CY (2) CY1108452T1 (en)
DE (4) DE60336275D1 (en)
DK (2) DK1908760T3 (en)
ES (5) ES2384118T3 (en)
GB (2) GB2393958A (en)
HK (1) HK1116188A1 (en)
SI (2) SI1908760T1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
KR101941467B1 (en) * 2010-12-22 2019-01-23 바이알 - 포르텔라 앤드 씨에이 에스에이 Crystalline forms and processes for their preparation
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2581556B2 (en) * 1986-05-06 1997-02-12 メレルダウファーマスーティカルズ インコーポレーテッド Novel dopamine beta-hydroxylase inhibitor
US4868210A (en) 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
PT757677E (en) * 1994-04-26 2003-11-28 Syntex Llc BENZOCYCLOHEXYLIMIDAZOLETION DERIVATIVES

Also Published As

Publication number Publication date
ES2361938T3 (en) 2011-06-24
ES2361939T3 (en) 2011-06-24
KR20120038014A (en) 2012-04-20
SI1408038T1 (en) 2008-10-31
KR101350741B1 (en) 2014-01-10
ATE550335T1 (en) 2012-04-15
ATE505465T1 (en) 2011-04-15
ATE500248T1 (en) 2011-03-15
DE60336276D1 (en) 2011-04-14
GB2393958A (en) 2004-04-14
ES2384118T3 (en) 2012-06-29
DK1408038T3 (en) 2008-11-24
CN1726211A (en) 2006-01-25
DE60336275D1 (en) 2011-04-14
GB2394223A (en) 2004-04-21
ATE403652T1 (en) 2008-08-15
GB0224306D0 (en) 2002-11-27
AR041589A1 (en) 2005-05-26
ES2364919T3 (en) 2011-09-16
CY1112457T1 (en) 2015-12-09
ATE500247T1 (en) 2011-03-15
SI1908760T1 (en) 2011-05-31
HK1116188A1 (en) 2008-12-19
GB2394223B (en) 2007-05-16
DE60322642D1 (en) 2008-09-18
ES2309279T3 (en) 2008-12-16
DE60336772D1 (en) 2011-05-26
AR095674A2 (en) 2015-11-04
CN100393715C (en) 2008-06-11
GB0223719D0 (en) 2002-11-20
DK1908760T3 (en) 2011-07-25

Similar Documents

Publication Publication Date Title
CY1108041T1 (en) RHO-CHINESE INHIBITIONS
CY1117217T1 (en) COMPOSITION AND ANTI-VISUAL ACTIVITY OF SUBSTITUTED AZAIDOLOOXOXIC PRODUCERS OF Piperazine
EA200300717A1 (en) Heterocyclylindazole and azazin-dazole compounds as 5-hydroxytriptamine-6-ligands
CY1107475T1 (en) RO-MOTION SUSPENSIONS
EA200401398A1 (en) SUBSTITUTED PHENYLACETAMIDES AND THEIR APPLICATION AS GLUKOKINASE ACTIVATORS
EA200100826A1 (en) 16-HALOGEN DERIVATIVES OF EPOTHILON, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION IN PHARMACEUTICS
ATE357434T1 (en) DISUBSTITUTED THIAZOLYLCARBOXANILIDES AND THEIR USE AS MICROBICIDES
CY1107985T1 (en) CCR1 competitors for the treatment of other degenerative inflammatory diseases
ATE543807T1 (en) AMPLIFIER OF GLUTAMATE RECEPTORS
DE60318177D1 (en) RHO-KINASE INHIBITORS
CY1105617T1 (en) NEW AROMATIC DERIVATIVES OF FLUOROGLYCOSIDES, DRUGS CONTAINING THESE COMPOUNDS AND THEIR USE
CY1105907T1 (en) NEW 1,2,4-THIADIAZOLE DERIVATIVES AS MELANOCORTIN RECEPTOR REGULATORS
BR0307432A (en) Difluoromethylthiazolylcarboxanilides
CY1107871T1 (en) Pyrimidine derivatives and their use as CB2 regulators
EA200301142A1 (en) DERIVATIVES OF HETEROCYCLILOXY-, -TIOOXY-AND-AMINOBENZAZOL AS A LYHANDS OF 5-HYDROXITRIPTAMINE-6
PA8571001A1 (en) 2- (2,6-DICLOROPHENYL) -DIARYLIMIDAZOLS
DE60330407D1 (en) Synthesis of epothilones, intermediates thereof, analogs and their use
FI924397A (en) SUBSTITUERADE PYRIMIDINER
EA200001133A1 (en) ANTIPICORNAVIRAL COMPOSITIONS, THEIR RECEIVING AND APPLICATION
ATE401877T1 (en) USE OF METHYLENAMIDE DERIVATIVES IN CARDIOVASCULAR DISEASES
CY1109964T1 (en) Heterocyclic Rings Synthesized with 1,4-Dihydropyridine, Their Preparation Process, Usage, and Their Compositions
CY1110537T1 (en) UNIONS AND METHODS FOR THE DISEASE EDUCATION
CY1113171T1 (en) ANTI-INFLAMMATING FACTORS
BRPI0417858A (en) compound, pharmaceutical composition, and use of a pharmaceutical composition
NO20044526L (en) Hemisterlin derivatives and uses thereof